We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1576
Ironwood Pharmaceuticals
IRWD
$683M
| $2.92M | ﹤0.01% |
219,762
+5,195
| +2% | +$57.3K |
|
1577
Hyatt Hotels
H
$16.9B
| $2.92M | ﹤0.01% |
32,557
-1
| -0% | -$78 |
|
1578
BOK Financial
BOKF
$8.78B
| $2.9M | ﹤0.01% |
33,217
+1,125
| +4% | +$91.7K |
|
1579
Par Pacific Holdings
PARR
$3.51B
| $2.9M | ﹤0.01% |
124,906
+10,271
| +9% | +$245K |
|
1580
Comtech Telecommunications
CMTL
$51.5M
| $2.9M | ﹤0.01% |
81,719
+4,827
| +6% | +$166K |
|
1581
Cushman & Wakefield Ltd
CWK
$3.29B
| $2.9M | ﹤0.01% |
141,846
+13,874
| +11% | +$261K |
|
1582
Gray Television
GTN
$441M
| $2.9M | ﹤0.01% |
135,205
+3,810
| +3% | +$70.7K |
|
1583
Universal Insurance Holdings
UVE
$1.23B
| $2.9M | ﹤0.01% |
103,491
+4,005
| +4% | +$116K |
|
1584
Griffon
GFF
$4.72B
| $2.89M | ﹤0.01% |
142,200
+7,054
| +5% | +$148K |
|
1585
Central Pacific Financial
CPF
$1.02B
| $2.88M | ﹤0.01% |
97,476
+5,365
| +6% | +$157K |
|
1586
Morningstar
MORN
$7.48B
| $2.88M | ﹤0.01% |
19,021
+464
| +3% | +$71.2K |
|
1587
Guardant Health
GH
$21.9B
| $2.88M | ﹤0.01% |
36,824
+983
| +3% | +$70.8K |
|
|
SCS
1588
DELISTED
Steelcase
SCS
| $2.87M | ﹤0.01% |
140,021
+2,558
| +2% | +$47.4K |
|
1589
Zscaler
ZS
$26.1B
| $2.87M | ﹤0.01% |
61,613
+1,295
| +2% | +$60.1K |
|
|
BFS
1590
Saul Centers
BFS
$825M
| $2.86M | ﹤0.01% |
54,153
+2,764
| +5% | +$146K |
|
|
KNL
1591
DELISTED
Knoll, Inc.
KNL
| $2.86M | ﹤0.01% |
113,149
+682
| +0.6% | +$18K |
|
1592
Casella Waste Systems
CWST
$5.82B
| $2.85M | ﹤0.01% |
61,984
+2,321
| +4% | +$102K |
|
|
MTOR
1593
DELISTED
MERITOR, Inc.
MTOR
| $2.85M | ﹤0.01% |
108,937
-43
| -0% | -$970 |
|
1594
Hackett Group
HCKT
$290M
| $2.85M | ﹤0.01% |
176,417
-691
| -0.4% | -$11K |
|
1595
Scorpio Tankers
STNG
$3.71B
| $2.84M | ﹤0.01% |
72,147
+3,331
| +5% | +$114K |
|
1596
Vanda Pharmaceuticals
VNDA
$306M
| $2.83M | ﹤0.01% |
172,367
+8,770
| +5% | +$133K |
|
|
TRST
1597
Trustco Bank Corp NY
TRST
$968M
| $2.83M | ﹤0.01% |
65,213
+2,804
| +4% | +$120K |
|
1598
Innovative Industrial Properties
IIPR
$1.7B
| $2.83M | ﹤0.01% |
37,244
+4,259
| +13% | +$330K |
|
1599
Apogee Enterprises
APOG
$897M
| $2.82M | ﹤0.01% |
86,880
+3,983
| +5% | +$148K |
|
|
PGTI
1600
DELISTED
PGT, Inc.
PGTI
| $2.82M | ﹤0.01% |
189,109
+9,431
| +5% | +$150K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.